ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Curis is launching a chemistry subsidiary in Shanghai that will advance small-molecule cancer therapies the firm began developing with Shanghai ChemPartner earlier this year. Curis says it plans to initiate a round-the-clock development program involving its U.S. operations in Cambridge, Mass.; the new subsidiary, Curis Shanghai; and ChemPartner chemists working under contract. Curis anticipates that its chemistry costs "will be reduced by 65-75% compared to outsourcing chemistry with traditional Western chemistry providers."
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X